Abbott Shares Jump 2.82% to $112.65 Ahead of Projected EPS Gain
Abbott shares rose 2.82% to $112.65, outperforming the S&P 500's 0.83% gain, while the stock is down 1.15% over the past month versus a 3.46% decline for the Medical sector. Analysts project next-quarter EPS of $1.15 (+5.5% YoY) and revenue of $11.03 billion (+6.5% YoY).
1. Trading Performance
In the latest session, Abbott shares closed at $112.65, rising 2.82% versus a 0.83% gain for the S&P 500, 0.5% for the Dow and 1.38% for the Nasdaq. Over the past month, the stock has declined 1.15%, outperforming a 3.46% drop in the Medical sector and a 2.65% fall in the S&P 500.
2. Upcoming Quarterly Forecast
Analysts forecast next-quarter EPS of $1.15, a 5.50% increase from the year-ago period, and revenue of $11.03 billion, up 6.53% year over year, reflecting expected growth in its infant formula, medical devices and pharmaceutical segments.
3. Valuation and Analyst Metrics
Abbott trades at a forward P/E of 19.3, roughly in line with the industry average of 19.33, and carries a PEG ratio of 1.74 versus the Medical – Products average of 1.68. The company holds a Zacks Rank of #3 (Hold) and its industry sits in the bottom 40% of Zacks Industry Rankings.